In a nutshell This study compared the effects on heart disease for SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes (T2D). It found that patients using SGLT2 inhibitor medications had lower rates of heart failure, heart attack, and stroke. Some background T2D is a disorder of high levels of glucose (sugar) in the blood. T2D...
Read MoreIn a nutshell The aim of this study was to investigate the relationship between the use of incretin-based anti-diabetic drugs and the risk of hospitalization due to heart failure. The main finding of the study was that the use of these drugs is not associated with an increased risk of hospitalization due to heart failure. Some background There...
Read More
In a nutshell This study aimed to investigate if the use of DPP-4 inhibitor drugs for the treatment of type 2 diabetes (T2D) was harmful or helpful in diabetic retinopathy (DR; eye disease). The main finding of this study was that DPP-4 inhibitors did not increase the overall risk of DR. Some background DPP-4 inhibitors (DPP4i) are a type drug used to...
Read MoreIn a nutshell This study reviewed data on the association between dipeptidyl peptidase-4 (DPP4) inhibitors and cancer development in patients with type 2 diabetes. They found that patients receiving DPP4 inhibitors were not at a greater risk of developing cancer. Some background Management of type 2 diabetes requires stringent blood...
Read More
In a nutshell This study determined the suitability of adding empagliflozin (Jardiance) to the combination of metformin (Glucophage) and linaglipton (Tradjenta) in type 2 diabetes. The authors concluded that adding empagliflozin was effective in patients whose blood sugar was not controlled by the combination of metformin and linaglipton alone. Some...
Read More
In a nutshell The authors aimed to determine the effect and safety of linagliptin (Tradjenta) in patients with type 2 diabetes with liver disease. The authors concluded that linagliptin is an effective and safe treatment in patients with type 2 diabetes and liver disease. Some background Diabetes raises the risk of non-alcohol...
Read MoreIn a nutshell This study aimed to determine the effectiveness and safety of linagliptin treatment in patients with mild and moderate kidney dysfunction. Some background Approximately 40% of diabetics develop kidney disease. This is associated with a higher risk of developing cardiovascular dysfunction (heart-related illness) and...
Read More
